<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274870</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: 14-237B</org_study_id>
    <nct_id>NCT02274870</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery</brief_title>
  <official_title>Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing
      total knee replacement (TKR). However the resulting motor blockade can lead to decreased
      quadriceps muscle strength and delayed functional recovery.The purpose of this study is to
      compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control
      and functional recovery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, active controlled study in patients undergoing total knee
      replacement. The objective of this study is to compare the efficacy of Liposome Bupivacaine,
      in managing postoperative pain, to standard of care CFNB. Following informed consent,
      patients will be randomized to one of two groups, Liposome Bupivacaine or active control,
      CFNB group.

      266 mg Liposome Bupivacaine plus Bupivicaine HCL (150mg) will be administered via local joint
      infiltration around the knee joint prior to wound closure. In the control group a CFNB will
      be placed for 48hrs prior to surgery. Outcomes measured included pain at rest, movement and
      quadriceps muscle strength on the first and second postoperative day.

      It is hypothesized that Liposome Bupivacaine will provide effective pain control and improved
      preservation of quadriceps muscle strength, in comparison to CFNB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity at Movement</measure>
    <time_frame>24hrs</time_frame>
    <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity at Rest</measure>
    <time_frame>24hrs</time_frame>
    <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivicaine Level</measure>
    <time_frame>72hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Levels</measure>
    <time_frame>48hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Level</measure>
    <time_frame>24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Level</measure>
    <time_frame>12hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Level</measure>
    <time_frame>4hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Level</measure>
    <time_frame>2hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Bupivacaine Level</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Liposome Bupivacaine,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposome Bupivacaine 266mg, Knee Infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposome Bupivacaine</intervention_name>
    <description>Administered via local tissue infiltration around the knee joint</description>
    <arm_group_label>Liposome Bupivacaine,</arm_group_label>
    <other_name>Bupivacaine Liposome, Injectable Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Administered via CFNB</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA Status I-III

          -  Scheduled to undergo primary unilateral total knee arthroplasty

        Exclusion Criteria:

          -  Patients who are pregnant or nursing

          -  Alcohol or narcotic dependence within the last 2 years

          -  Condition requiring regular use of analgesia that may confound post surgical
             assessments as determined by principle investigator

          -  BMI &gt; 40kg/m2

          -  Contraindication to acetaminophen, morphine, oxycodone, ketorolac, epinephrine, or
             pathological conditions potentially aggravated by epinephrine

          -  Allergies to amide-type local anesthetics

          -  Any disease condition or lab result that could complicate a patients postoperative
             recovery

          -  History of hypotension

          -  Abnormal liver, renal or cardiac function

          -  Other physical, mental or medical conditions that, in the opinion of the investigator,
             make study participation inadvisable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Marino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franklin</name>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <zip>11580</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2018</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Joseph Marino M.D.</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine</title>
          <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine HCl</title>
          <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine,</title>
          <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine HCl</title>
          <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.19" spread="7.59"/>
                    <measurement group_id="B2" value="62.29" spread="8.11"/>
                    <measurement group_id="B3" value="63.22" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, Continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.13" spread="4.53"/>
                    <measurement group_id="B2" value="32.57" spread="4.55"/>
                    <measurement group_id="B3" value="32.84" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity at Movement</title>
        <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
        <time_frame>24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine,</title>
            <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity at Movement</title>
          <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
          <units>VAS Scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" lower_limit="8.42" upper_limit="9.48"/>
                    <measurement group_id="O2" value="7.91" lower_limit="7.19" upper_limit="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity at Rest</title>
        <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
        <time_frame>24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity at Rest</title>
          <description>Pain intensity at maximum knee flexion measured using a 0-10 visual analog scale.
Higher values represent a higher pain intensity or worse outcome.</description>
          <units>VAS Scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" lower_limit="4.18" upper_limit="5.98"/>
                    <measurement group_id="O2" value="5.16" lower_limit="4.17" upper_limit="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <time_frame>24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <units>Morphine milligram equivalents</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.91" lower_limit="22.11" upper_limit="35.70"/>
                    <measurement group_id="O2" value="26.32" lower_limit="20.60" upper_limit="32.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivicaine Level</title>
        <time_frame>72hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivicaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.01"/>
                    <measurement group_id="O2" value="1.08" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Levels</title>
        <time_frame>48hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposome Bupivacaine,</title>
            <description>Liposome Bupivacaine 266mg, Knee Infiltration
Liposome Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Levels</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.19"/>
                    <measurement group_id="O2" value="1.76" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Level</title>
        <time_frame>24hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.16"/>
                    <measurement group_id="O2" value="1.16" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Level</title>
        <time_frame>12hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.23"/>
                    <measurement group_id="O2" value="0.74" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Level</title>
        <time_frame>4hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.18"/>
                    <measurement group_id="O2" value="0.44" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Level</title>
        <time_frame>2hrs</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.1"/>
                    <measurement group_id="O2" value="0.29" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Bupivacaine Level</title>
        <time_frame>Baseline</time_frame>
        <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Liposomal Bupivacaine 266mg Knee Infiltration
Liposomal Bupivacaine: administered via local tissue infiltration around the knee joint.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Bupivacaine Level</title>
          <population>Of the 32 and 33 participants in each arm 11 and 12 were allocated respectively to receive a blood draw</population>
          <units>microgram per mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine</title>
          <description>Liposomal Bupivacaine 266mg, Knee Infiltration
Liposomal Bupivacaine: Administered via local tissue infiltration around the knee joint</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine HCl</title>
          <description>Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
Bupivacaine HCl: Administered via CFNB</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pains</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PONV</sub_title>
                <description>Postoperative nausea and vomiting</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Knee Swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Research, Anesthesiology</name_or_title>
      <organization>Northwell Health</organization>
      <phone>718-470-7630</phone>
      <email>odowling@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

